User:S4403863: Difference between revisions
No edit summary |
|||
(9 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
Teo Jia Ling Tricia; Bench E; 31/08/2016 <br> | Teo Jia Ling Tricia; Bench E; 31/08/2016 <br> | ||
<ref>MICR3004</ref> | <ref>MICR3004</ref> | ||
[[Image:veipa.jpg|frame|right|150px| Scanning electron micrograph of <i>Veillonella parvula</i>]] | |||
==Classification== | ==Classification== | ||
===Higher order taxa=== | ===Higher order taxa=== | ||
Bacteria | Kingdom - Bacteria; Phylum - Firmicutes; Class - Negativicutes; Order - Selenomonadales; Family - Veillonellaceae; Genus –-Veillonella | ||
===Species=== | ===Species=== | ||
''Veillonella parvula'' | ''Veillonella parvula''; Strain [https://www.atcc.org/products/all/10790.aspx ATCC 10790] | ||
Strain ATCC 10790 | |||
==Description and significance== | ==Description and significance== | ||
Line 42: | Line 41: | ||
==Pathology== | ==Pathology== | ||
<i>V. parvula</i> is generally considered to be of low virulence. However, a study by Lupens <i>et al.</i> depicted the ability of <i>V. parvula</i> to enhance the pathogenicity of other bacterium, when co-cultured together, and its implication on polymicrobial diseases such as caries and periodontitis. It was shown that co-culture of <i>Streptococcus</i> mutans and <i>V. parvula</i> in a biofilm changes the physiology of <i>S. mutans</i> and enhances its | <i>V. parvula</i> is generally considered to be of low virulence. However, a study by Lupens <i>et al.</i> depicted the ability of <i>V. parvula</i> to enhance the pathogenicity of other bacterium, when co-cultured together, and its implication on polymicrobial diseases such as caries and periodontitis. It was shown that co-culture of <i>Streptococcus</i> mutans and <i>V. parvula</i> in a biofilm changes the physiology of <i>S. mutans</i> and enhances its properties against antimicrobials <sup>[[#References|[16]]]</sup>. In rare cases, <i>V. parvula</i> can also cause deep neck infections, chronic maxillary sinusitis and bacteraemia, meningitis, endocarditis, tonsillitis, discitis, prosthetic joint infection <sup>[[#References|[1]]]</sup><sup>[[#References|[17]]]</sup>. | ||
Presence of LPS on <i>V. parvula</i> cell wall was shown to significantly elevate IL-6 production in immune cells in a Toll-like receptor 4 (TLR4)-dependent process, resulting in inflammatory and immune response which occur during infections <sup>[[#References|[17]]]</sup>. | Presence of LPS on <i>V. parvula</i> cell wall was shown to significantly elevate IL-6 production in immune cells in a Toll-like receptor 4 (TLR4)-dependent process, resulting in inflammatory and immune response which occur during infections <sup>[[#References|[17]]]</sup>. | ||
Line 48: | Line 47: | ||
Risk factors of <i>V. parvula</i> infections include individuals with periodontal disease, immune deficiency, premature birth and use of intravenous drugs <sup>[[#References|[17]]]</sup>. | Risk factors of <i>V. parvula</i> infections include individuals with periodontal disease, immune deficiency, premature birth and use of intravenous drugs <sup>[[#References|[17]]]</sup>. | ||
Bacteria is resistant to vancomycin, tetracycline, aminoglycosides and ciprofloxacin | Bacteria is resistant to vancomycin, tetracycline, aminoglycosides and ciprofloxacin <sup>[[#References|[9]]]</sup>, but infection can typically be treated with penicillin, cephalosporin, clindamycin, metronidazole, chloramphenicol <sup>[[#References|[18]]]</sup>. | ||
==Application to biotechnology== | ==Application to biotechnology== | ||
Line 54: | Line 53: | ||
Studies on <i>Veillonella</i> species have been limited to physiological characterizations due to its complexity in genetic manipulability. This makes it one of the least understood organism, in terms of biology and pathogenic potential, in the human microbiome, despite its prevalence in the human body <sup>[[#References|[12]]]</sup>. | Studies on <i>Veillonella</i> species have been limited to physiological characterizations due to its complexity in genetic manipulability. This makes it one of the least understood organism, in terms of biology and pathogenic potential, in the human microbiome, despite its prevalence in the human body <sup>[[#References|[12]]]</sup>. | ||
Liu <i>et al.</i> | The first genetic transformation of the genus was reported to be done by Liu <i>et al.</i> in <i>V. atypica</i>, using a shutter vector, paving the way for future use of <i>V. atypica</i> as a genetic system for <i>Veillonella</i> studies <sup>[[#References|[19]]]</sup>. | ||
There no current reported use of <i>V. parvula</i> in biotechnology. However, the lactic acid metabolism property of <i>V. parvula</i> could potentially be exploited in the farming industry. | |||
Ruminal acidosis has been a significant concern in the farming industry, which causes death and weight loss in sheep and cattle. Rumen lactic acidosis occurs when the ruminant consumes large amounts of feeds high in ruminal fermentable carbohydrates, which they are unaccustomed to. This leads to the production of lactic acid in the rumen, reducing the efficiency of rumen flora and fermentation <sup>[[#References|[20]]]</sup>. A previous study by Kung <i>et al.</i> showed that the use of another lactate-utilizing bacteria, <i>Megasphaera elsdenii</i>, is able to reduce lactate levels in vitro. This finding could possibly be translated in vivo <sup>[[#References|[21]]]</sup> to prevent ruminal acidosis. This opens the possibility to <i>V. parvula</i> being potentially used as an alternate form of ruminal acidosis treatment and prevention in the future. | |||
Ruminal acidosis has been a significant concern in the farming industry, which causes death and weight loss in sheep and cattle. Rumen lactic acidosis occurs when the ruminant consumes large amounts of feeds high in ruminal fermentable carbohydrates, which they are unaccustomed to. This leads to the production of lactic acid in the rumen, reducing the efficiency of rumen flora and fermentation <sup>[[#References|[20]]]</sup>. A previous study by Kung <i>et al.</i> showed that the use of another lactate-utilizing bacteria, <i>Megasphaera elsdenii</i>, is able to reduce lactate levels in vitro. This finding could possibly be translated in vivo <sup>[[#References|[21]]]</sup>. <i>V. parvula</i> | |||
==Current research== | ==Current research== |
Latest revision as of 03:19, 23 September 2016
Teo Jia Ling Tricia; Bench E; 31/08/2016
[1]
Classification
Higher order taxa
Kingdom - Bacteria; Phylum - Firmicutes; Class - Negativicutes; Order - Selenomonadales; Family - Veillonellaceae; Genus –-Veillonella
Species
Veillonella parvula; Strain ATCC 10790
Description and significance
Veillonella parvula is a non-motile, non-spore forming, anaerobic gram-negative coccus. It grows in pairs or in chains and is about 0.3 to 0.5 μm in diameter [1].
It was first described by Veillon and Zuber in 1898 as “Staphylococcus parvulus” [2] before being renamed as V. parvula by Prévot in 1933 [3]. Early experiments were conducted on V. parvula oral isolates [4]. It is commonly found in the human oral cavity, especially in subgingival dental plaque. It is also found in gastrointestinal tract and vagina, as part of the microflora [1][4][5]. It is involved in establishing early microbial colonies in dental plaque formation, along with Streptococcus and other species [6][7] and can make up 10% of the early colonizing bacteria on the enamel [8]. However, it can also be associated with dental and other infections [1][9].
It plays an important role in microbial food chain by metabolizing end products of carbohydrate-fermenting bacteria, such as lactic acid bacteria, allowing it to symbiotically establish itself in anaerobic environments [10][11]. Despite its prevalence in the human body, studies on this bacterium has been extremely limited due to its difficulty in manipulation. Thus, it is still not well understood [12].
12 species have been described under the same genus [12], of which 6 species have been suggested to facilitate the development of oral biofilms [13]. V. parvula is species that is the most abundant in the human oral cavity and gastrointestinal tract [12].
Genome structure
V. parvula is the only fully assembled genome in the Veillonella genus and comprises of 2,132,142 bp genome size circular chromosome, with 38.6% GC content. It encodes 1, 920 genes, of which 73.6% are functional, 61 RNAs and 1,859 proteins [1].
Cell structure and metabolism
V. parvula is non motile and has a distinctive lipopolysaccharide (LPS) on its outer membrane [1]. Its cell wall also consists of cadaverine and putrescine, which are essential for growth [14].
Biofilms develop when initial colonizers, streptococci and actinomyces, bind to host-derived receptors in the saliva film-coated tooth enamel. This allows subsequent binding of Veillonella and other bacteria via coadhesion. Coaggregation, subsequently follows. This involves binding and cell-to-cell recognition between genetically distinct microbial species, resulting in plaque formation. Saliva is a complex nutrient source. Development of plaque is thought to involve spatial organization of different bacteria and interactions between species, which in combination, is able to metabolize latent nutrients into usable ones to be further processed by other species, allowing nutrients in saliva to be fully utilized [11].
V. parvula is involved in plaque development as it is able to interact metabolically with streptococci. Consumption of sucrose is then converted to glucose or fructose by streptococci. Most glucose is converted to lactate which is subsequently utilized by Veillonella, converting it into propionate, acetate and carbon dioxide for energy. This sets up a metabolic food chain in the dental plaque. V. parvula is also able to utilize other fermented organic acids such as pyruvate, malate and fumarate. On the other hand, it is unable to utilize carbohydrates and amino acids for energy [10][11].
Some sucrose is converted by streptococcal extracellular glucosyltransferase into dextran, which allows Veillonella to adhere and establish itself on tooth surfaces. Fructose, a product of dextran synthesis, can then be incorporated into Veillonella lipopolysaccharide (LPS), contributing to the production of endotoxic LPS, expressed on the cell surface [10].
Ecology
V. parvula is an anaerobe bacteria, found in subgingival plaque [15]. Development of thick plaque provides favourable anaerobic conditions, thus V. parvula is mostly distributed in deeper plaque layers. It is found to increase in numbers in presence of gingival infection [10].
In the development of biofilm and plaque, V. parvula associates with other oral microbes to establish itself in the oral microbial ecosystem via coadhesion and coaggregation. Coaggregation is mediated by binding of lectin-like adhesins to receptor polysaccharide on streptococci [5][11].
Pathology
V. parvula is generally considered to be of low virulence. However, a study by Lupens et al. depicted the ability of V. parvula to enhance the pathogenicity of other bacterium, when co-cultured together, and its implication on polymicrobial diseases such as caries and periodontitis. It was shown that co-culture of Streptococcus mutans and V. parvula in a biofilm changes the physiology of S. mutans and enhances its properties against antimicrobials [16]. In rare cases, V. parvula can also cause deep neck infections, chronic maxillary sinusitis and bacteraemia, meningitis, endocarditis, tonsillitis, discitis, prosthetic joint infection [1][17].
Presence of LPS on V. parvula cell wall was shown to significantly elevate IL-6 production in immune cells in a Toll-like receptor 4 (TLR4)-dependent process, resulting in inflammatory and immune response which occur during infections [17].
Risk factors of V. parvula infections include individuals with periodontal disease, immune deficiency, premature birth and use of intravenous drugs [17].
Bacteria is resistant to vancomycin, tetracycline, aminoglycosides and ciprofloxacin [9], but infection can typically be treated with penicillin, cephalosporin, clindamycin, metronidazole, chloramphenicol [18].
Application to biotechnology
Studies on Veillonella species have been limited to physiological characterizations due to its complexity in genetic manipulability. This makes it one of the least understood organism, in terms of biology and pathogenic potential, in the human microbiome, despite its prevalence in the human body [12].
The first genetic transformation of the genus was reported to be done by Liu et al. in V. atypica, using a shutter vector, paving the way for future use of V. atypica as a genetic system for Veillonella studies [19].
There no current reported use of V. parvula in biotechnology. However, the lactic acid metabolism property of V. parvula could potentially be exploited in the farming industry.
Ruminal acidosis has been a significant concern in the farming industry, which causes death and weight loss in sheep and cattle. Rumen lactic acidosis occurs when the ruminant consumes large amounts of feeds high in ruminal fermentable carbohydrates, which they are unaccustomed to. This leads to the production of lactic acid in the rumen, reducing the efficiency of rumen flora and fermentation [20]. A previous study by Kung et al. showed that the use of another lactate-utilizing bacteria, Megasphaera elsdenii, is able to reduce lactate levels in vitro. This finding could possibly be translated in vivo [21] to prevent ruminal acidosis. This opens the possibility to V. parvula being potentially used as an alternate form of ruminal acidosis treatment and prevention in the future.
Current research
V. parvula is a major hydrogen sulphide (H2S) producer, making it a major cause of bad breath. However, little research was done on physiological properties affecting of H2S production by V. parvula. A recent study by Washio et al., investigated the effects of cell growth stages and environmental factors, such as pH and presence of lactate, on H2S production. H2S is produced from L-Cysteine, found in saliva due to epithelial cell desquamation. Keratin, a major protein in desquamated epithelial cell, may serve as a source of L-Cysteine for H2S production by V. parvula. It was reported that H2S production is influenced by changes in pH and lactate, which is likely to be influenced by the production of lactic acid by streptococci [22].
Another recent study on the distribution and frequency of Veillonella species on tongue biofilms of Thai children showed that Veillonella species were more frequently detected in individuals with poor oral hygiene and thus may be a marker for oral hygiene status [23].
References
1. Gronow, S., Welnitz, S., Lapidus, A., Nolan, M., Ivanova, N., Glavina Del Rio, T., et al. (2010) Complete genome sequence of Veillonella parvula type strain (Te3). Stand Genomic Sci 2: 57–65.
2. Veillon, A., and Zuber, M. (1898) Recherches sur quelques microbes strictement anaérobies et leur rôle en pathologie. Arch Med Exp 1898 10: 517–545.
3. Prévot, A. (1933) Études de systématique bactérienne. I: Lois générale. II: Cocci anaérobies. Ann Sci Nat Bot 15: 23–260.
4. Rogosa, M. (1964) The Genus Veillonella. J Bacteriol 87: 162–170.
5. Chalmers, N.I., Palmer, R.J., Cisar, J.O., and Kolenbrander, P.E. (2008) Characterization of a Streptococcus sp.-Veillonella sp. community micromanipulated from dental plaque. J Bacteriol 190: 8145–8154.
6. Diaz, P.I., Chalmers, N.I., Rickard, A.H., Kong, C., Milburn, C.L., Palmer, R.J., et al. (2006) Molecular characterization of subject-specific oral microflora during initial colonization of enamel. Appl Environ Microbiol 72: 2837–48
7. Li, J., Helmerhorst, E.J., Leone, C.W., Troxler, R.F., Yaskell, T., Haffajee, A.D., et al. (2004) Identification of early microbial colonizers in human dental biofilm. J Appl Microbiol 97: 1311–1318.
8. Vesth, T., Ozen, A., Andersen, S.C., Kaas, R.S., Lukjancenko, O., Bohlin, J., et al. (2013) Veillonella , Firmicutes : Microbes disguised as Gram negatives. 431–448.
11. Periasamy, S., and Kolenbrander, P.E. (2010) Central role of the early colonizer Veillonella sp. in establishing multispecies biofilm communities with initial, middle, and late colonizers of enamel. J Bacteriol 192: 2965–2972.
12. Liu, J., Merritt, J., and Qi, F. (2011) Genetic transformation of Veillonella parvula. FEMS Microbiol Lett 322: 138–144
14. Kanio, Y., and Nakamura, K. (1987) Putrescine and cadaverine are constituents of peptidoglycan in Veillonella alcalescens and Veillonella parvula. J Bacteriol 169: 2881–2884.
15. Palmer, R.J., Diaz, P.I., and Kolenbrander, P.E. (2006) Rapid succession within the Veillonella population of a developing human oral biofilm in situ. J Bacteriol 188: 4117–4124.
16. Sbi, L., Kara, D., Bandounas, L., Mj, J., Fra, W., Bruning, O., and Tm, B. (2008) Effect of Veillonella parvula on the antimicrobial resistance and gene expression of Streptococcus mutans grown in a dual-species biofilm. 183–189.
18. Fisher, R.G., and Denison, M.R. (1996) Veillonella parvula bacteremia without an underlying source. J Clin Microbiol 34: 3235–3236.
19. Liu, J., Xie, Z., Merritt, J., and Qi, F. (2012) Establishment of a tractable genetic transformation system in Veillonella spp. Appl Environ Microbiol 78: 3488–3491.
21. Hession, A., and Kung, L. (2014) Vitro Lactate Accumulation in Ruminal Fermentations by Inoculation with Megasphaera. J Anim Sci 1995: 250–256.
22. Washio, J., Shimada, Y., Yamada, M., Sakamaki, R., and Takahashi, N. (2014) Effects of pH and lactate on hydrogen sulfide production by oral Veillonella spp. Appl Environ Microbiol 80: 4184–4188.
- ↑ MICR3004
This page is written by Tricia Teo for the MICR3004 course, Semester 2, 2016